Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 20:18 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 17,084 | $0.00 Strike: $34.35 | $0.00 |
DisclosureSEC source: 0001897965-26-000002 · form4-05262026_080529.xml · derivative · entry 1 Hall Kimball · CIK 0001897965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,084 Underlying: Class A Common Stock · 17,084 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| May 14, 2025 Filed May 16, 2025 20:08 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001415889-25-013415 · form4-05162025_080530.xml · derivative · entry 1 Hall Kimball · CIK 0001897965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Class A Common Stock · 14,000 shares Expires 2035-05-13 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:12 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $42.69 | $0.00 |
DisclosureSEC source: 0001415889-24-013473 · form4-05172024_080545.xml · derivative · entry 1 Hall Kimball · CIK 0001897965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,000 Underlying: Class A Common Stock · 14,000 shares Expires 2034-05-14 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:13 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-23-029018 · doc4.xml · derivative · entry 1 Hall Kimball · CIK 0001897965 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2033-05-09 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:16 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 9,925 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0001209191-22-032189 · doc4.xml · derivative · entry 1 Hall Kimball · CIK 0001897965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,925 Underlying: Class A Common Stock · 9,925 shares Expires 2032-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| December 10, 2021 Filed Dec 13, 2021 21:06 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 19,850 | $0.00 Strike: $24.36 | $0.00 |
DisclosureSEC source: 0001209191-21-069233 · doc4.xml · derivative · entry 1 Hall Kimball · CIK 0001897965 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,850 Underlying: Class A Common Stock · 19,850 shares Expires 2031-12-09 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over a three-year period, subject to the reporting person's continuous service on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.